News and Announcements
Second Patient In Human Cancer Trial Begins Treatment
- Published November 24, 2014 2:54PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Source: ASX; Published: 24 November 2014
PharmAust Limited (ASX:PAA & PAA)) is pleased to report that it has initiated treatment of the second patient on 21 November 2014 in its ‘First in Man’ trial with PPL-1. To date the drug appears safe and no adverse events have been observed. The patient will receive PPL-1 daily for 28 days. The patient is suffering from lung cancer with metastases to other organs.
PharmAust’s Executive Chairmna Dr Roger Aston said “In addition to the second patient referred above, a further two patients have entered screening and, subject to their suitability, will be recruited and also begin treatment on 2 and 9 December respectively’.
Please download the document below to view the full announcement.
Company Updates
Built on discipline, not complexity: inside an ASX equities income strategy
Haydn Froggatt and Zac Brabin have decades of derivatives experience between them and access to almost any strategy in the market. They use two of the simplest structures available, and wrote 202 positions with them last year. Published by Fairway Capital Management. Based on an interview with co-founders Haydn Froggatt and Zac Brabin. Two traders, […]
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
Backed By Leading Investment Groups and Family Offices
